Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases

Rhea-AI Summary

Evogene (Nasdaq: EVGN), Systasy Bioscience and LMU University Hospital Munich announced a collaborative program on Feb. 11, 2026 to develop novel therapies for neutrophil-driven hyper-inflammatory diseases, including IBD. The effort is supported by a pan-European EUREKA grant and includes participation from the Weizmann Institute.

Evogene will lead small-molecule discovery using its ChemPass AI™; Systasy will apply its PathwayProfiler DNA barcoding assays; LMU will validate leads in human stem cell–derived neutrophil models and advance biomarkers and translational plans.

News Market Reaction

+0.99%

7 alerts

+0.99% News Effect

+2.4% Peak Tracked

-13.7% Trough Tracked

+$92K Valuation Impact

$9M Market Cap

0.5x Rel. Volume

On the day this news was published, EVGN gained 0.99%, reflecting a mild positive market reaction. Argus tracked a peak move of +2.4% during that session. Argus tracked a trough of -13.7% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $92K to the company's valuation, bringing the market cap to $9M at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $0.9600 Vol: Volume 9,420,306 is about...

high vol

$0.9600 Last Close

Volume Volume 9,420,306 is about 8x the 20-day average of 1,177,664, signaling heavy trading interest. high

Technical Shares at 1.01 are trading below the 200-day MA of 1.21, reflecting a longer-term downtrend.

Peers on Argus

EVGN fell 7.34% while several biotech peers were also weak (e.g., ERNA -5.19%, L...

1 Down

EVGN fell 7.34% while several biotech peers were also weak (e.g., ERNA -5.19%, LYRA -4.55%, KZIA -3.87%), though MBIO gained 2.48%, pointing to mixed, stock-specific pressure rather than a uniform sector move.

Historical Context

5 past events · Latest: Feb 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 09	Advisory board additions	Positive	+0.9%	Appointment of two professors to strengthen ChemPass AI scientific leadership.
Feb 04	Licensing agreement	Positive	+4.8%	Exclusive worldwide license for BMC128 microbiome-based cancer therapeutic.
Jan 07	R&D collaboration	Positive	-0.9%	Collaboration with Unravel Biosciences on first-in-class demyelination therapy.
Dec 30	Executive appointment	Positive	-3.2%	Appointment of VP Business Development to scale AI-driven discovery efforts.
Nov 11	Strategic partnership	Positive	+4.6%	Casterra–Fantini collaboration to mechanize large-scale commercial castor farming.

Pattern Detected

Recent news—mainly collaborations and leadership additions—has produced mixed reactions, with both rallies and selloffs following ostensibly positive announcements.

Recent Company History

Over the last few months, Evogene has focused on partnerships and strengthening its scientific and business leadership. On Feb 4, 2026, a licensing deal for microbiome therapy BMC128 saw shares rise 4.81%. Collaborations, such as the Unravel Biosciences deal on Jan 7, 2026, and Casterra’s agricultural partnership on Nov 11, 2025, also drew attention but with varied price outcomes. Management additions in December 2025 and February 2026 similarly triggered both gains and pullbacks, underscoring inconsistent market responses to strategic news.

Market Pulse Summary

This announcement highlights an AI-driven collaboration targeting neutrophil-mediated inflammatory d...

Analysis

This announcement highlights an AI-driven collaboration targeting neutrophil-mediated inflammatory diseases, including IBD, by combining Evogene’s ChemPass AI with advanced stem-cell and pathway-profiling platforms. It extends a recent series of R&D and licensing partnerships and follows management additions supporting the same strategy. Investors might track how this program progresses toward validated lead compounds, biomarker development, and potential clinical plans, while also watching future filings and updates for evidence of execution milestones and partnering traction.

Key Terms

neutrophil, inflammatory bowel disease (IBD), inborn error of immunity, granulocytes, +4 more

8 terms

neutrophil medical

"hyper-inflammatory diseases driven by dysregulated neutrophil activity, including"

A neutrophil is a type of white blood cell that acts like a first responder against infections, quickly arriving at sites of injury or illness to help fight invading germs. For investors, neutrophil counts are important because drops or spikes can signal safety risks or effectiveness issues in drug trials and treatments, which can affect regulatory approval, labeling, market acceptance, and a company’s financial outlook.

inflammatory bowel disease (IBD) medical

"neutrophil activity, including inflammatory bowel disease (IBD). The collaboration"

A group of long-lasting conditions that cause ongoing inflammation in the digestive tract, most commonly Crohn’s disease and ulcerative colitis, producing symptoms such as abdominal pain, diarrhea and weight loss. For investors, IBD matters because it represents a sizable, chronic patient population that creates persistent demand for drugs, diagnostics and procedures; changes in treatment options, regulatory approvals or reimbursement can significantly affect healthcare company revenues and valuations.

inborn error of immunity medical

"identified a novel inborn error of immunity associated with reduced"

A genetic condition where a person is born with a flaw in their immune system that makes them unusually vulnerable to infections, inflammation, or autoimmune problems. For investors, these conditions define clear patient groups, create demand for specialized diagnostics and long-term therapies, and often qualify treatments for incentives like orphan-drug status—think of it as a factory defect in the body’s defense system that creates predictable medical needs and market opportunities.

granulocytes medical

"associated with reduced numbers of neutrophil granulocytes, yet without marked"

Granulocytes are a group of white blood cells that act as the body’s first responders to infection and injury; they contain tiny packets of enzymes and chemicals that help detect and destroy microbes. For investors, granulocyte levels and function matter because they are common measures in clinical trials, diagnostic tests, and safety monitoring—changes can signal drug effectiveness or harmful side effects, much like a smoke alarm indicating a problem in a building.

stem cell-derived neutrophils medical

"platform for multiplexed profiling of stem cell-derived neutrophils, generating"

Stem cell-derived neutrophils are neutrophils — a type of short-lived white blood cell that fights infections — grown in the lab from stem cells rather than collected from donors. For investors, they represent a potential new class of therapies, diagnostics, and testing materials: like a factory producing replacement frontline soldiers, they could address donor shortages, speed drug development, and create scalable products whose clinical benefit, manufacturing cost and regulatory approval determine commercial value.

biomarker medical

"supporting biomarker discovery and translational strategies aimed at"

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

in vitro medical

"validate lead compounds in innovative human in vitro neutrophil models,"

In vitro describes laboratory tests performed on cells, tissues, or biological molecules outside a living body—literally “in glass,” such as in test tubes or dishes. For investors, in vitro results are an early sign that a drug or technology has a desired effect under controlled conditions, but they don’t guarantee it will work or be safe in animals or people; think of them as a prototype tested on a bench rather than in real-world use.

precision diagnostics medical

"will apply advanced stem cell biology and precision diagnostics to validate"

Precision diagnostics are medical tests that go beyond yes/no answers to identify specific characteristics of a patient’s condition—such as genetic changes, precise disease subtypes, or markers that predict how someone will respond to a treatment. Like a high-resolution map guiding a mechanic to the exact part that needs fixing, these tests help doctors choose the most effective therapies and avoid ineffective ones. For investors, precision diagnostics matter because they can drive demand for targeted treatments, create partnerships with drug makers, influence reimbursement decisions, and often command higher prices than one-size-fits-all tests.

AI-generated analysis. Not financial advice.

The collaboration is supported by a pan-European EUREKA grant, with participation of the Weizmann Institute of Science

REHOVOT, Israel and MUNICH, Germany, Feb. 11, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, Systasy Bioscience GmbH, a biotechnology company leveraging proprietary DNA barcoding technology for hyper-multiplexed pathway profiling in patient-derived iPSC models to accelerate drug discovery for complex disorders, and LMU University Hospital Munich, today announced a collaboration aiming to accelerate the development of novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The collaboration brings together Evogene, Systasy, and Prof. Christoph Klein (LMU University Hospital in collaboration with the German Center for Child and Adolescent Health), with additional participation from the Weizmann Institute of Science in Rehovot, Israel. The program is supported by a prestigious pan-European EUREKA grant, which was awarded to advance this international drug discovery effort.

 

 

 

 

Hundreds of millions of people worldwide are affected by inflammatory and immune-mediated diseases in which neutrophils play a key pathogenic role^[1],[2]. Despite being first responders in inflammation and key drivers of tissue damage, neutrophils are not directly targeted by existing therapies, creating a significant unmet need for safe, selective, and effective new treatment approaches.

The collaboration builds on Prof. Klein's clinical and scientific studies and insights derived from a rare genetic immunodeficiency. His team identified a novel inborn error of immunity associated with reduced numbers of neutrophil granulocytes, yet without marked functional defects of the immune system. By translating this naturally occurring rare condition into a therapeutic strategy, the collaboration aims to develop targeted therapies that modulate excessive neutrophil driven inflammation while potentially minimizing safety risks commonly associated with immune suppression.

The collaboration partners contribute complementary and synergistic expertise and technologies. Evogene will lead the small-molecule drug discovery effort using its proprietary ChemPass AI™ generative engine to design, optimize, and prioritize novel inhibitors. Together with the Weizmann Institute of Science, computational design will be tightly integrated with high-throughput experimental validation. Systasy will leverage its proprietary DNA barcoding technology to expand the PathwayProfiler™ platform for multiplexed profiling of stem cell-derived neutrophils, generating high-dimensional functional data to validate and refine Evogene's AI-designed inhibitors. The Department of Pediatrics at LMU's Dr. von Hauner Children's Hospital, led by Prof. Christoph Klein, will apply advanced stem cell biology and precision diagnostics to validate lead compounds in innovative human in vitro neutrophil models, while also supporting biomarker discovery and translational strategies aimed at personalized immunology and future clinical development.

Mr. Ofer Haviv, Evogene's President and CEO, stated: "We are excited to join forces with Systasy's and Prof. Klein's scientific expertise in launching this international effort, bringing therapeutic solutions to inflammatory conditions affecting many patients. The support of the prestigious EUREKA grant is a strong vote of confidence in this synergistic collaboration, as well as further acknowledgment of the uniqueness of ChemPass AI™, Evogene's AI-driven tech engine for small molecule discovery and optimization. By integrating AI-driven discovery with experimental excellence and clinical insight, we aim to advance innovative therapeutic concepts with clear clinical and commercial potential."

Dr. Sven Wichert, CEO of Systasy Bioscience, commented: "This EUREKA-funded collaboration marks a pivotal step for Systasy in extending our PathwayProfiler platform to neutrophil biology. Partnering with Evogene's AI innovation, LMU's clinical expertise, and Weizmann's validation strengths positions us to deliver breakthrough therapies addressing unmet needs in hyper-inflammatory diseases. Our hyper-multiplexed, patient-derived assays will provide the high-quality functional data essential for accelerating discovery and ensuring translational success."

Professor Christoph Klein, Chair, Department of Pediatrics, LMU University Hospital, is equally thrilled about this new collaborative project: "We care for children with rare diseases every day; occasionally, we discover novel genetic defects and elucidate pathomechanisms. Only rarely, however, is clinical and scientific knowledge translated into the development of novel therapeutic strategies. Thanks to the EUREKA-funded grant, we are now in the privileged position to advance the field substantially."

About Evogene Ltd.

Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries.

At the core of its technology is ChemPass AI™, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs.

Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs. We call this approach "Real-World Innovation."

Learn more at: www.evogene.com.

About Systasy Bioscience GmbH

Systasy Bioscience GmbH is a biotechnology company specializing in automated induced pluripotent stem cell (iPSC)-based solutions that accelerate drug discovery and development for pharma and biotech partners. Founded in 2012 and headquartered in Munich, Systasy integrates advanced cell culture automation, high-content assay platforms, and data-driven workflows to enable more predictive, human-relevant models across a broad range of disease areas. Through close scientific collaboration with industry and academic stakeholders, the company is committed to improving the efficiency, quality, and translational value of preclinical research to ultimately advance better therapies to patients.

Learn more at: www.systasy.de.

About LMU University Hospital Munich and the DZKJ

The LMU University Hospital is one of Europe's leading university hospitals, combining top-level patient care, biomedical research, and medical education as part of the Ludwig-Maximilians-Universität München (LMU). It covers the full spectrum of medical specialties and is internationally recognized for excellence in translational and clinical work. The group led by Prof. Klein focuses on rare diseases and innovative approaches to their diagnosis and treatment.

The German Center for Child and Adolescent Health (DZKJ) is a nationwide network connecting leading institutions across Germany with the shared goal of improving the health of children and adolescents through interdisciplinary and translational approaches.

Together, the LMU University Hospital and the DZKJ foster close collaboration between clinical practice and scientific innovation, accelerating the development of improved prevention strategies, diagnostics, and therapies for children and adolescents.

Learn more at: www.lmu-klinikum.de; www.ccrc-hauner.de/research-labs/klein-lab/939888339a9fcb00; https://dzkj.org.

Forward-Looking Statements

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may," "could," "expects," "hopes," "intends," "anticipates," "plans," "believes," "scheduled," "estimates," "demonstrates" or words of similar meaning. For example, Evogene is using forward-looking statements in this press release when it discusses the potential success of the collaboration to develop targeted therapies that modulate excessive neutrophil driven inflammation while potentially minimizing safety risks commonly associated with immune suppression, and the potential success of the collaboration to accelerate discovery and ensure translational success. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene, including, the aftermath of the recent war between Israel and each of (i) the terrorist groups, Hamas and Hezbollah, (ii) Iran, and (iii) other regional terrorist groups supported by Iran, and any destabilizations in Israel, neighboring territories or the Middle East region, as well as those additional risk factors identified those risk factors contained in Evogene's reports filed with the applicable securities authority. In addition, Evogene rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

^1. Gelabert-Mora, Andrea, et al. JAAD international 2025.
^2. Herrero-Cervera et al. Cellular & molecular immunology 2022.

Logo: https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg
Logo: https://mma.prnewswire.com/media/2901992/Systasy_Logo.jpg
Logo: https://mma.prnewswire.com/media/2901993/LMU_Klinikum_Logo.jpg

Evogene Investor Relations Contact:
ir@evogene.com
+972-8-9311901

Systasy Contact:
info@systasy.de
+49 (0) 151-51263366

LMU University Hospital Contact: 
christoph.klein@med.uni-muenchen.de
+49 (0)89-4400-57701

View original content:https://www.prnewswire.com/news-releases/evogene-systasy-and-lmu-university-hospital-munich-announce-a-collaboration-to-develop-novel-therapies-for-neutrophil-derived-inflammatory-diseases-302685020.html

SOURCE Evogene; Systasy; LMU University Hospital Munich

FAQ

What is the goal of the Evogene, Systasy and LMU collaboration (EVGN) announced Feb. 11, 2026?

The goal is to develop targeted therapies for neutrophil-driven hyper-inflammatory diseases, including IBD. According to Evogene, the program combines AI-driven small-molecule design, high-throughput functional profiling, and human stem cell models to accelerate translational development.

How is Evogene contributing to the EVGN collaboration and what technology will it use?

Evogene will lead the small-molecule discovery effort using its ChemPass AI™ generative engine. According to Evogene, ChemPass AI™ will design, optimize and prioritize novel inhibitors integrated with experimental validation from partners.

What role does Systasy Bioscience play in the collaboration announced Feb. 11, 2026?

Systasy will expand its PathwayProfiler platform to profile stem cell–derived neutrophils using DNA barcoding. According to Systasy, its hyper-multiplexed assays will generate high-dimensional functional data to validate and refine AI-designed inhibitors.

What clinical and translational work will LMU University Hospital Munich perform in the EVGN collaboration?

LMU will validate lead compounds in human in vitro neutrophil models and support biomarker discovery. According to LMU, the Department of Pediatrics will apply stem cell biology and precision diagnostics to advance translational strategies for future clinical development.

What funding supports the collaboration between Evogene, Systasy, LMU and Weizmann?

The program is supported by a pan-European EUREKA grant awarded to advance the international drug discovery effort. According to Evogene, the EUREKA grant provides backing for the integrated computational, experimental and clinical research collaboration.